Position in ORGO
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$48,779
+$3,100 QoQ
Shares Held
20,074
+89.8% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#75
of 135 holders
Holding Since
Mar 2022
5 quarters on record
Voting authority
Sole 14%
Shared 0%
None 86%
Common Shares in ORGO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026CAPTRUST FINANCIAL ADVISORS holds $43,412,538 across 29 Drug Manufacturers - Specialty & Generic names. ORGO ranks #27 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
121,151 | $8,705,910 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
45,360 | $7,644,974 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
9,855 | $5,339,734 | |
| 4 | VTRS |
Viatris Inc
|
197,717 | $3,139,745 | |
| 5 | HLN |
Haleon plc
|
263,202 | $2,455,674 | |
| 6 | HROW |
Harrow, Inc.
|
56,414 | $2,395,902 | |
| 7 | TAK |
Takeda Pharmaceutical Co Ltd
|
143,998 | $2,308,287 | |
| 8 | ALKS |
Alkermes plc.
|
42,278 | $2,215,367 |
All Filings in ORGO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $48,779 | 20,074 | Shares | Sole | 2026-08-13 | |
| 2025-03-31 | $45,679 | 10,574 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $37,344 | 11,670 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $36,061 | 12,609 | Shares | Sole | 2024-11-14 | |
| 2022-03-31 | $16,916 | 2,220 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||